CVS and its PBM agree to pay $45 million to Illinois for failing to pass drug rebates

Taking stock of the drug industry, from the lab to the medicine chest

July 24, 2024 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

Matt Rourke/AP STAT+ | CVS and its PBM agree to pay $45 million to Illinois for failing to pass drug rebates "This will keep CVS from holding on to any manufacturer dollars," said Chris Brown of McAteer, a consulting firm. "This rips down a wall." By Ed Silverman STAT+ | Pfizer gene therapy reduced hemophilia bleeds, but questions remain Phase 3 results set stage for approval, but analysts point to weak demand for gene therapy by hemophilia patients. By Jason Mast STAT+ | Sage suffers pipeline setback with failure of drug to treat essential tremor New results are a significant setback for Sage's neurology pipeline, and its effort to develop a successful medicine beyond Zurzuvae. By Adam Feuerstein

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2024, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser